These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 21769434)

  • 1. Clinical screening assay for EGFR exon 19 mutations using PNA-clamp smart amplification process version 2 in lung adenocarcinoma.
    Araki T; Shimizu K; Nakamura T; Baba M; Kawai Y; Nakamura K; Mitani Y; Obayashi K; Aomori T; Fujita Y; Miyamae Y; Kakegawa S; Kaira K; Lezhava A; Hayashizaki Y; Takeyoshi I; Yamamoto K
    Oncol Rep; 2011 Nov; 26(5):1213-9. PubMed ID: 21769434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of peptide nucleic acid (PNA)-clamp smart amplification process version 2 (SmartAmp2) for clinical diagnosis of KRAS codon 12 mutations in lung adenocarcinoma: comparison of PNA-clamp SmartAmp2 and PCR-related methods.
    Araki T; Shimizu K; Nakamura K; Nakamura T; Mitani Y; Obayashi K; Fujita Y; Kakegawa S; Miyamae Y; Kaira K; Ishidao T; Lezhava A; Hayashizaki Y; Takeyoshi I; Yamamoto K
    J Mol Diagn; 2010 Jan; 12(1):118-24. PubMed ID: 20007840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
    Kim HJ; Lee KY; Kim YC; Kim KS; Lee SY; Jang TW; Lee MK; Shin KC; Lee GH; Lee JC; Lee JE; Kim SY
    Lung Cancer; 2012 Mar; 75(3):321-5. PubMed ID: 21930325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of EGFR mutation detection between the tissue and cytology using direct sequencing, pyrosequencing and peptide nucleic acid clamping in lung adenocarcinoma: Korean multicentre study.
    Min KW; Kim WS; Jang SJ; Choi YD; Chang S; Jung SH; Kim L; Roh MS; Lee CS; Shim JW; Kim MJ; Lee GK;
    QJM; 2016 Mar; 109(3):167-73. PubMed ID: 26031706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive efficacy of low burden EGFR mutation detected by next-generation sequencing on response to EGFR tyrosine kinase inhibitors in non-small-cell lung carcinoma.
    Kim HS; Sung JS; Yang SJ; Kwon NJ; Jin L; Kim ST; Park KH; Shin SW; Kim HK; Kang JH; Kim JO; Park JY; Choi JE; Yoon H; Park CK; Yang KS; Seo JS; Kim YH
    PLoS One; 2013; 8(12):e81975. PubMed ID: 24376508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultrasensitive and quantitative detection of EGFR mutations in plasma samples from patients with non-small-cell lung cancer using a dual PNA clamping-mediated LNA-PNA PCR clamp.
    Zhang S; Chen Z; Huang C; Ding C; Li C; Chen J; Zhao J; Miao L
    Analyst; 2019 Feb; 144(5):1718-1724. PubMed ID: 30663747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide Nucleic Acid Clamping Versus Direct Sequencing for the Detection of EGFR Gene Mutation in Patients with Non-small Cell Lung Cancer.
    Yoon SH; Choi YD; Oh IJ; Kim KS; Choi H; Chang J; Shin HJ; Park CK; Kim YC
    Cancer Res Treat; 2015 Oct; 47(4):661-9. PubMed ID: 25715768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
    Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MassARRAY, pyrosequencing, and PNA clamping for EGFR mutation detection in lung cancer tissue and cytological samples: a multicenter study.
    Min KW; Kim WS; Jang SJ; Choi YD; Chang S; Jung SH; Kim L; Roh MS; Lee CS; Shim JW; Kim MJ; Lee GK;
    J Cancer Res Clin Oncol; 2016 Oct; 142(10):2209-16. PubMed ID: 27535566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of a locked nucleic acid based wild-type blocking PCR for the detection of EGFR exon 18/19 mutations.
    Vliegen L; Dooms C; De Kelver W; Verbeken E; Vansteenkiste J; Vandenberghe P
    Diagn Pathol; 2015 May; 10():57. PubMed ID: 26022577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.
    Tsai TH; Su KY; Wu SG; Chang YL; Luo SC; Jan IS; Yu CJ; Yu SL; Shih JY; Yang PC
    Eur Respir J; 2012 Mar; 39(3):677-84. PubMed ID: 21719485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
    Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
    Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of EGFR mutation status in lung adenocarcinoma specimens with different proportions of tumor cells using two methods of differential sensitivity.
    Han HS; Lim SN; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Son SM; Choi SY; Lee HC; Lee OJ
    J Thorac Oncol; 2012 Feb; 7(2):355-64. PubMed ID: 22157369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presence of the minor EGFR T790M mutation is associated with drug-sensitive EGFR mutations in lung adenocarcinoma patients.
    Hashida S; Soh J; Toyooka S; Tanaka T; Furukawa M; Shien K; Yamamoto H; Asano H; Tsukuda K; Hagiwara K; Miyoshi S
    Oncol Rep; 2014 Jul; 32(1):145-52. PubMed ID: 24842519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenocarcinoma of the lung with rare insertion mutation in EGFR exon 19 that had partial response to gefitinib: a case report.
    Kozlov V; Karpov I; Kovalenko S; Shamanin V
    Exp Oncol; 2017 Jul; 39(2):155-156. PubMed ID: 29483495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DISSECT Method Using PNA-LNA Clamp Improves Detection of EGFR T790m Mutation.
    Guha M; Castellanos-Rizaldos E; Makrigiorgos GM
    PLoS One; 2013; 8(6):e67782. PubMed ID: 23805327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers.
    Tanaka T; Nagai Y; Miyazawa H; Koyama N; Matsuoka S; Sutani A; Huqun ; Udagawa K; Murayama Y; Nagata M; Shimizu Y; Ikebuchi K; Kanazawa M; Kobayashi K; Hagiwara K
    Cancer Sci; 2007 Feb; 98(2):246-52. PubMed ID: 17233841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas.
    Pan Q; Pao W; Ladanyi M
    J Mol Diagn; 2005 Aug; 7(3):396-403. PubMed ID: 16049312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
    Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
    Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.